Zoetis earns license for Cytopoint skin therapyJanuary 4, 2017Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”
SPONSORED CONTENTGive your patients FAST diarrhea reliefProbiotics or nutrition? Prioritize Hill's Prescription Diet GIB nutrition clinically shown to resolve diarrhea in as little as 24 hours. + Learn More
